Overview

Avelumab/Gemcitabine in Sarcomatoid RCC

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Antibodies, Monoclonal
Avelumab
Gemcitabine